---
$id: https://graph.org.ai/products/commodity/51131736
$type: Product
source: UNSPSC
code: "51131736"
title: "Ozagrel"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Ozagrel

**UNSPSC Code**: 51131736
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an enzyme inhibitor and antiplatelet agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L256JB984D. European Medicines Agency schedules Ozagrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09581MIG. Ozagrel generally arises in the molecular formula C13H12N2O2. The term OZAGREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) OZAGREL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ozagrel under HS 29332990 and SITC 51573. As of Q4 2014, OZAGREL remains the US FDA Preferred Term for this commodity. Ozagrel bears US NLM identifiers UMLS ID C0069392 and NCI Concept Code C66288. SMILES: CL.OC(=O)/C=C/C1CCC(CN2CCNC2)CC1.O.

